ERBB2 and non-small cell lung carcinoma: Since several clinical trials are testing different Her2-targeted therapies in NSCLC with different Her2 alterations, a large multi-institutional study is required to assess the Her2 abnormalities and their molecular associations since this may affect the outcome and the choice of treatment.